Monoclonal antibody approved for the treatment of moderate-to-severe Crohn's disease

被引：0
|
作者：
不详
机构：
来源：
FORMULARY | 2008年 / 43卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：40 / +
页数：2
相关论文
共 50 条
  • [21] Treatment of severe Crohn's disease with anti-CD4 monoclonal antibody
    CanvaDelcambre, V
    Jacquot, S
    Robinet, E
    Lemann, M
    Drouet, C
    Labalette, M
    Dessaint, JP
    Bengoufa, D
    Rabian, C
    Modigliani, R
    Wijdenes, J
    Revillard, JP
    Colombel, JF
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1996, 10 (05) : 721 - 727
  • [22] Upadacitinib for the treatment of moderate to severe Crohn's disease
    Kessing, Richard
    [J]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2024, 62 (01): : 25 - 25
  • [23] Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease
    Tuskey, Anne
    Behm, Brian W.
    [J]. CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2014, 7 : 173 - 179
  • [24] PATIENT AND PHYSICIAN PREFERENCES IN SELECTING A BIOLOGIC FOR MODERATE-TO-SEVERE CROHN'S DISEASE
    Athavale, G.
    Lau, G.
    Muser, E.
    Ingham, M.
    Deshpande, A.
    Hadker, N.
    [J]. VALUE IN HEALTH, 2017, 20 (05) : A224 - A225
  • [25] Effectiveness, safety and persistence of treatment with ustekinumab in a cohort of patients with moderate-to-severe refractory Crohn's Disease
    Morales Bermudez, A. I.
    Bravo Aranda, A. M.
    Martinez Burgos, M.
    Olmedo Martin, R.
    [J]. JOURNAL OF CROHNS & COLITIS, 2021, 15 : S509 - S510
  • [26] The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis
    Shahidi, Neal
    Bressler, Brian
    Panaccione, Remo
    [J]. THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2016, 9 (03) : 330 - 338
  • [27] Open Label Ustekinumab for the Treatment of Anti-TNFα Refractory Moderate-to-Severe Crohn's Disease
    Rosen, Melissa
    Scherl, Ellen
    Rotman, Stephen
    Bosworth, Brian
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S486 - S487
  • [28] Adalimumab treatment reduces extraintestinal manifestations in patients with moderate-to-severe Crohn's disease: a pooled analysis
    Louis, E. J.
    Lofberg, R.
    Reinisch, W.
    Schwartz, D.
    Maa, J-F
    Berg, S.
    Huang, B.
    Wang, A. W.
    Robinson, A. M.
    Pappalardo, B.
    [J]. JOURNAL OF CROHNS & COLITIS, 2016, 10 : S351 - S352
  • [29] Is memantine a breakthrough in the treatment of moderate-to-severe Alzheimer's disease?
    Doggrell, S
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (10) : 1857 - 1860
  • [30] Crohn's disease treatment approved
    Nightingale, SL
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (13): : 1128 - 1128
12345